Head to Head Survey: Biogen (BIIB) and Its Peers

01:08 EDT 25 Sep 2017 | Topix

Biogen is one of 45 public companies in the "Biopharmaceuticals" industry, but how does it contrast to its peers? We will compare Biogen to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, earnings, valuation and risk. Biogen currently has a consensus target price of $329.27, suggesting a potential upside of 3.40%.

Original Article: Head to Head Survey: Biogen (BIIB) and Its Peers


More From BioPortfolio on "Head to Head Survey: Biogen (BIIB) and Its Peers"

Quick Search

Relevant Topic

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...